IP Library › Granted Patent US 10,385,376
Granted Patent B2
US 10,385,376 · App. 15/523,107 · Granted Aug 20, 2019

21-hydroxylation of steroids

Inventors: Claus Lattemann (Frankfurt am Main, DE); Thomas Stillger (Frankfurt am Main, DE); Bernd Janocha (Frankfurt am Main, DE); Hans-Falk Rasser (Frankfurt am Main, DE); Sebastian Rissom (Frankfurt am Main, DE); Simone Anderko (Saarbrücken, DE); Rita Bernhardt (Saarbrücken, DE); Frank Hannemann (Saarbrücken, DE)
Assignee: SANOFI
C12P33/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,376
App. No.
15/523,107
Granted
Aug 20, 2019
Kind
B2
Abstract

Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.

Claims (22)

1. A process for the hydroxylation of the carbon atom 21 of a steroid, comprising the steps of:

(a) providing a cell expressing:

(i) a heterologous CYP21A2 protein or a functional variant thereof;

(ii) at least one heterologous electron transfer system capable of transferring electrons to CYP21A2; and

(iii) one or more chaperones facilitating folding of CYP21A2; and

(b) adding the steroid to the cell,

wherein the steroid is medrane or deltamedrane.

2. The process of claim 1 , further comprising a step (c) of extracting the 21-hydroxylated steroid from the supernatant of the cell.

3. The process of claim 1 , further comprising adding one or more cell permeabilizing agents to the cell after step (b).

4. The process of claim 1 , wherein the cell is a resting cell.

5. The process of claim 1 , wherein the cell is a prokaryotic cell or a eukaryotic cell.

6. The process of claim 1 , wherein the at least one heterologous electron transfer system comprises:

(a) a CYP21A2 reductase, and/or

(b) a ferredoxin reductase.

7. The process of claim 1 , wherein the one or more chaperones are recombinantly expressed chaperones.

8. The process of claim 1 , wherein the expression of at least one tryptophanase gene is reduced or abolished in the cell.

9. The process of claim 1 , wherein the cell further expresses a heterologous gene encoding for an enzyme catalyzing a step in the heme biosynthesis pathway.

10. The process of claim 1 , wherein the genes encoding for (i), (ii), and optionally (iii) are comprised in one or more expression cassettes which are integrated into the cell genome.

11. The process of claim 5 , wherein the cell is an E. coli cell.

12. The process of claim 5 , wherein the cell is a yeast cell.

13. The process of claim 9 , wherein the heterologous gene encoding for an enzyme catalyzing a step in the heme biosynthesis pathway is a hemA gene.

14. The process of claim 6 , wherein the at least one heterologous electron transfer system comprises an NADPH-dependent ferredoxin reductase and a ferredoxin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2023
From: SANOFI
To: EUROAPI FRANCE
Reel/Frame 065978/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2017
From: LATTEMANN, CLAUS; STILLGER, THOMAS; JANOCHA, BERND; RASSER, HANS-FALK; RISSOM, SEBASTIAN; ANDERKO, SIMONE; BERNHARDT, RITA; HANNEMANN, FRANK
To: SANOFI
Reel/Frame 042205/0748 →
Priority Claims (1)
EP 14306740 · Oct 30, 2014 · regional
Continuity (1)
Related Publication 20170321241A1 · Nov 9, 2017
Cited By (1)
US 12,195,767